Oncology & Cancer

Bortezomib beneficial in graft-versus-host disease prophylaxis

(HealthDay) -- Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor (MMUD) reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) may benefit from a prophylactic, ...

Oncology & Cancer

Novel drug regimen can improve stem cell transplantation outcomes

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to ...

Oncology & Cancer

Study links father's age and risk of blood cancer as an adult

A new study links a father's age at birth to the risk that his child will develop blood and immune system cancers as an adult, particularly for only children. The study, which appears in the American Journal of Epidemiology, ...

Oncology & Cancer

ICU mortality similar for patients with hematologic CA ± chemo

(HealthDay)—Short-term mortality is similar among patients with hematologic cancer who receive chemotherapy while in the intensive care unit (ICU) versus those who do not, according to a study published online May 4 in ...

page 10 from 18